Endocrinology

Conditions: Pancreatic Cancer
Interventions: Drug: TTI-101
Sponsors: University of Colorado, Denver; Tvardi Therapeutics, Incorporated
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Cystic Fibrosis-related Diabetes; Cystic Fibrosis
Interventions: Drug: Empagliflozin; Other: Placebo Control
Sponsors: Amir Moheet
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Obesity; Diabetes Mellitus, Type 2
Interventions: Drug: BI 456906; Drug: Placebo
Sponsors: Boehringer Ingelheim
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Diabetes Mellitus
Interventions: Device: Continuous Glucose Monitor Dexcom G6 PRO
Sponsors: Mayo Clinic
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Adrenoleukodystrophy
Interventions: Drug: MIN-102; Drug: Placebos
Sponsors: Minoryx Therapeutics, S.L.
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Ovarian Cancer; Fallopian Tube Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Malignant Ovarian Brenner Tumor; Ovarian Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Transitional Cell Carcinoma
Interventions: Other: Exercise Counseling; Other: Aerobic Exercise; Other: Physiological Support; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Other: Best Practice
Sponsors: University of Washington; National Cancer Institute (NCI)
Terminated

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas
Interventions: Drug: [212Pb] VMT-α-NET; Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT
Sponsors: David Bushnell; Holden Comprehensive Cancer Center; National Cancer Institute (NCI); Perspective Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Cancer of Pancreas
Interventions: Other: Non-Human Subject Research study.
Sponsors: University of Central Florida
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Ductal Carcinoma in Situ
Interventions: Drug: Tamoxifen; Drug: Exemestane; Drug: Letrozole; Drug: Anastrazole; Drug: Testosterone + Anastrazole; Drug: Elacestrant; Drug: Z-endoxifen
Sponsors: QuantumLeap Healthcare Collaborative
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Conditions: Recurrent Ovarian Cancer
Interventions: Drug: CPI-0209; Drug: carboplatin
Sponsors: Lan Coffman; MorphoSys AG; National Cancer Institute (NCI)
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.